Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital.

Aim: Our goal was to describe a precision medicine program in a regional academic hospital, characterize features of included patients and present early data on clinical impact.

Materials And Methods: We prospectively included 163 eligible patients with late-stage cancer of any diagnosis from June 2020 to May 2022 in the Proseq Cancer trial. Molecular profiling of new or fresh frozen tumor biopsies was done by WES and RNAseq with parallel sequencing of non-tumoral DNA as individual reference.

Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.

Aims: To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in high-risk groups.

Methods: In a nationwide, population-based cohort study, we identified all individuals treated with sotrovimab (N = 2933) and stratified them by 4 high-risk groups: (A) malignant haematological disease, (B) solid organ transplantation, (C) anti-CD20 therapy ≤1 year and (D) other risks. Cox regression analysis was used to calculate hazard ratios for hospitalization, death and associated prognostic factors.

Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study.

Background: There are limited data on outcomes of moderate to severe coronavirus disease 2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real-world setting. We sought to compare the effectiveness of standard of care (SOC) alone versus SOC plus remdesivir and dexamethasone.

Methods: Two population-based nationwide cohorts of individuals hospitalized with COVID-19 during February through December 2020 were studied.

Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars.

Purpose: The aim of this study was to describe the implementation and uptake of biosimilar trastuzumab in Denmark compared with other European countries.

Methods: European data for usage of trastuzumab was supplied by IQVIA™, using the MIDAS® dataset. A comparison was performed based on market share estimated in sales volume.

The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.

Purpose: A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).

Improving Medication Safety in Psychiatry - A Controlled Intervention Study of Nurse Involvement in Avoidance of Potentially Inappropriate Prescriptions.

The aim of this controlled, before-and-after study in the Department of Psychiatry in a university hospital in Denmark was to examine the potential effects and characteristics of nurses reviewing psychiatric patients' medication records to identify potentially inappropriate prescriptions (PIPs). The control group and the intervention group each consisted of two bed units chosen based on patients' diagnoses and age categories. There were 396 patients (age ≥18 years) included in the study.

Treatment with enzyme replacement therapy during pregnancy in a patient with Pompe disease.

Pregnancy is in general physically demanding, even more so for women with hereditary muscular diseases (HMDs). With increasing numbers of women with HMD reaching reproductive age, there is a growing need for research into what impact pregnancy can have on their clinical condition. A 25-year-old woman was diagnosed with Pompe disease at the age of 22 and began enzyme replacement therapy (ERT) right away.

Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation.

Aims: Switching between oral anticoagulants and treatment discontinuation are common events related to therapy with non-vitamin K antagonist oral anticoagulants (NOACs). However, knowledge on the reasons leading to these treatment changes is scarce. The aim of this study was to identify clinical events preceding anticoagulant switching and NOAC discontinuation during oral anticoagulant therapy in patients with atrial fibrillation.

Medication errors involving anticoagulants: Data from the Danish patient safety database.

Reporting of adverse incidents is mandatory in Denmark. All reported adverse incidents are made anonymously, and stored in an encrypted database. It is the purpose of this descriptive study to describe the severity of adverse medication incidents caused by oral anticoagulants in hospitals.

Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.

Patients with atrial fibrillation discontinuing anticoagulant therapy are left unprotected against ischaemic stroke. Further, switching between oral anticoagulants may be associated with a transiently increased risk of bleeding or thromboembolism. However, there is a paucity of real-life data on pattern of switching and discontinuation of oral anticoagulants.

Clinical Pharmacology in Denmark in 2016 - 40 Years with the Danish Society of Clinical Pharmacology and 20 Years as a Medical Speciality.

The Danish Society of Clinical Pharmacology was founded in 1976, and mainly thanks to the persistent efforts of the society, clinical pharmacology became an independent medical speciality in Denmark in 1996. Since then, clinical pharmacology has gone from strength to strength. In the Danish healthcare system, clinical pharmacology has established itself as an indispensible part of the efforts to promote the rational, safe and economic use of drugs.

[Serious bleeding complications caused by warfarin with international normalized ratio 2.1].

The risk of bleeding due to anticoagulation therapy with warfarin rises exponentially, when the international normalized ratio (INR) exceeds 4.5. We present a 52-year-old male admitted to the hospital with severe bleeding in the lower limbs caused by warfarin.

[Methods for systematic listing of medication in the elderly].

To improve medication in the elderly several screening tools have been developed. The most used tool is the Beers 2003 criteria; however, the newer STOPP/START criteria have proven more effective and easier to use. Based on the literature we aim to compare these tools according to a list of desired properties and to suggest the best template for a Danish tool, though it is still to be determined, whether the identification and correction of potentially inappropriate medication leads to a better outcome in terms of decreased morbidity and mortality and improved health economics.

[Fourth generation oral contraceptives are associated with a higher risk of venous thromboembolism compared to second generation].

It has been widely discussed whether fourth generation oral contraceptives (OC) are associated with a higher risk of venous thromboembolism (VTE) compared to second generation. Lack of randomized controlled trials, methodological problems and inconsistent criteria for the VTE event has led to conflicting results. Three newly published studies utilising improved methodology show that fourth generation OC are associated with an increased risk of VTE compared to second generation OC.

[Gastrointestinal bleeding after treatment with ticagrelor].

Ticagrelor is a reversible inhibitor of platelet-aggregation, and is used instead of clopidogrel in the treatment of acute coronary syndrome (ACS). Ticagrelor has documented better outcomes as shown in the PLATO-study, when compared to clopidogrel. However, more major non-CABG bleedings are observed with ticagrelor.

New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Oral anticoagulant therapy (OAT) is widely used to prevent and treat thromboembolic events. Traditionally, warfarin has been the drug of choice and, indeed, this drug is effective and provides a more than 60% reduction in stroke risk in patients with atrial fibrillation. However, OAT entails an increased bleeding risk, and management of this is challenging.

Percutaneous coronary intervention without onsite cardiac surgery.

Introduction: Danish health authorities have major concerns with regard to the risk and the quality of care of percutaneous coronary intervention (PCI) without onsite cardiac surgery. We report the results of the first Danish PCI centre without onsite cardiac surgery.

Material And Methods: A total of 245 patients underwent 254 elective PCIs during a six-month study period.